Stockscreener 앱 받기
4.37
4.55%
0.19
시장 영업 전:
4.46
0.09
+2.06%
전일 마감가:
$4.18
열려 있는:
$4.18
하루 거래량:
19.06M
Relative Volume:
0.94
시가총액:
$1.75B
수익:
$64.60M
순이익/손실:
$-377.75M
주가수익비율:
-2.8194
EPS:
-1.55
순현금흐름:
$-335.64M
1주 성능:
+7.11%
1개월 성능:
-23.33%
6개월 성능:
-42.35%
1년 성능:
-47.22%
1일 변동 폭
$4.18
$4.52
1주일 범위
$4.10
$4.69
52주 변동 폭
$3.79
$12.36
리커젼 파마 Stock (RXRX) Company Profile
명칭
Recursion Pharmaceuticals Inc
전화
(385) 269-0203
주소
41S RIO GRANDE STREET, SALT LAKE CITY
RXRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.37 | 1.78B | 64.60M | -377.75M | -335.64M | -1.55 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
리커젼 파마 Stock (RXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-05-22 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 개시 | Needham | Buy |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-04 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 개시 | Berenberg | Buy |
| 2021-05-11 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Goldman | Neutral |
| 2021-05-11 | 개시 | JP Morgan | Neutral |
| 2021-05-11 | 개시 | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 개시 | SVB Leerink | Outperform |
모두보기
리커젼 파마 주식(RXRX)의 최신 뉴스
Was Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)? - MSN
Recursion to Participate in Upcoming Investor Conferences - Yahoo Finance
Did Jim Cramer Nail or Miss These 11 Stock Predictions? - Insider Monkey
Bank of America Securities Reaffirms Their Hold Rating on Recursion Pharmaceuticals (RXRX) - The Globe and Mail
(RXRX) Trading Signals - news.stocktradersdaily.com
RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside? - Zacks Investment Research
3 Monster Stocks to Hold for the Next 10 Years - Mitrade
3 Monster Stocks to Hold for the Next 10 Years - The Motley Fool
Recursion Pharmaceuticals (NasdaqGS:RXRX) Reports Increased Net Loss Despite Rising Sales - Yahoo Finance
(RXRX) Technical Data - news.stocktradersdaily.com
Transcript : Recursion Pharmaceuticals, Inc. Presents at 53rd Annual JPMorgan Global Technology, Media and Communications Conference, May-15-2025 10 - marketscreener.com
Recursion Pharmaceuticals, Inc. (RXRX) Nosedives 36.55% As AI Drug Discovery Dreams Stall - Insider Monkey
Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock - Zacks Investment Research
10 Most Popular AI Stocks to Avoid Now - Insider Monkey
Recursion Pharmaceuticals: High-Risk Play Getting Riskier By The Quarter (NASDAQ:RXRX) - Seeking Alpha
Recursion Pharmaceuticals, Inc. (RXRX): Among the Best Artificial Intelligence Stocks Under $50 to Buy Now - MSN
13 Best Artificial Intelligence Stocks Under $50 to Buy Now - Insider Monkey
Transcript : Recursion Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10 - marketscreener.com
Should You Buy This Beaten-Down Artificial Intelligence (AI) Stock on the Dip? - The Globe and Mail
How Recursion Is Industrializing Clinical Trials With AI - Clinical Leader
Recursion Pharmaceuticals outlines focused R&D pipeline with multiple catalysts through 2026 - MSN
Recursion Pharmaceuticals files prospectus supplement By Investing.com - Investing.com India
Recursion Pharmaceuticals files prospectus supplement - Investing.com Australia
Why Recursion Pharmaceuticals Stock Plummeted 24% This Week - Mitrade
Recursion Pharmaceuticals Registers Shares for Resale - TipRanks
(RXRX) Long Term Investment Analysis - news.stocktradersdaily.com
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2025 Earnings Call Transcript - MSN
Retail Traders Bearish On Recursion Pharma Ahead of Q1 Results Despite Positive Tupelo Trial Data - MSN
RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates - MSN
Earnings Release: Here's Why Analysts Cut Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Price Target To US$7.43 - Yahoo Finance
Why Recursion Pharmaceuticals Stock Is Plummeting Today - The Globe and Mail
Recursion axes drug programmes to streamline pipeline - Yahoo Finance
BofA Adjusts Price Target for RXRX Following Pipeline Changes | RXRX Stock News - GuruFocus
Recursion Pharmaceuticals Inc (RXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships ... By GuruFocus - Investing.com Canada
Recursion Pharmaceuticals (RXRX) Advances Drug Programs with Str - GuruFocus
Recursion Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Recursion Pharmaceuticals: Q1 Earnings Snapshot - MySA
Recursion Pharmaceuticals’ Earnings Call: Balancing Success and Challenges - TipRanks
Recursion Pharmaceuticals Q1 2025 Earnings: EPS Beats Estimates at -$0.50, Revenue Misses at $15 Million - GuruFocus
Recursion Pharmaceuticals (RXRX) Reports Q1 Earnings: EPS Surpas - GuruFocus
Recursion (RXRX) Reports Q1 Revenue Shortfall, Focuses on Stream - GuruFocus
Why Recursion Pharmaceuticals Stock Was Getting Mashed on Monday - Mitrade
Earnings call transcript: Recursion Pharmaceuticals Q1 2025 results miss estimates By Investing.com - Investing.com South Africa
Earnings call transcript: Recursion Pharmaceuticals Q1 2025 results miss estimates - Investing.com Nigeria
Recursion Pharmaceuticals (NasdaqGS:RXRX) Reports Q1 Sales Increase and REC-4881 Trial Results - Yahoo Finance
리커젼 파마 (RXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.48%
자본화:
|
볼륨(24시간):